Tretinoin (RETINOIC ACID)
Commonly Found In
Overview
Retinoic acid (tretinoin) is the biologically active, acidic form of vitamin A and the most potent topical retinoid used in dermatology. It works by binding directly to nuclear retinoic acid receptors (RARs), regulating gene expression to accelerate epidermal cell turnover, normalize follicular keratinization, and stimulate collagen synthesis in the dermis. Clinical evidence from decades of research indicates it is among the most effective topical treatments for acne vulgaris, photoaged skin, and hyperpigmentation, including post-inflammatory discoloration. Because of its high potency and well-documented irritation profileβincluding redness, peeling, and dryness especially during initial weeks of useβretinoic acid is classified as a prescription drug in the EU, US, and most other jurisdictions, and is banned from cosmetic formulations in the EU (Annex II/375).
Also known as: Tretinoin, All-trans retinoic acid, All-trans tretinoin, Vitamin A acid, Retin-A (brand), trans-Retinoic acid
Key Benefits
Clinical evidence indicates retinoic acid is among the most rigorously studied topical agents for acne, photoaging, and hyperpigmentation. Studies suggest it accelerates cell turnover, stimulates collagen synthesis, and normalizes follicular keratinization, leading to measurable improvements in fine lines, skin texture, and dark spots with consistent use under medical supervision.
Supporting Research
- β’ Kligman AM et al. (1986). Topical tretinoin for photoaged skin. Journal of the American Academy of Dermatology, 15(4 Pt 2), 836-859. Demonstrated significant improvement in fine wrinkling and rough texture after 16 weeks.
- β’ Leyden JJ et al. (1992). Tretinoin and acne. Journal of the American Academy of Dermatology, 27(6 Pt 2), S68-S71. Confirmed efficacy in reducing comedones and inflammatory acne lesions.
- β’ Griffiths CE et al. (1993). Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. Archives of Dermatology, 129(4), 419-425. Compared 0.025% vs 0.1% tretinoin efficacy and tolerability.
Skin Compatibility Ratings
Comedogenic Rating
Non-comedogenic; in fact, tretinoin is used clinically to reduce comedones in acne treatment.
Source: Draelos ZD & DiNardo JC (2006). A re-evaluation of the comedogenicity concept. JAAD, 54(3), 507-512.
Irritancy Rating
Well-documented irritation including erythema, scaling, and dryness, especially during the first 2-4 weeks of use ('retinoid dermatitis'). Irritation is dose-dependent and generally decreases with continued use.
Source: Griffiths CE et al. (1993). Archives of Dermatology, 129(4), 419-425. CIR Expert Panel assessments of retinoid irritancy.
Typical Use Concentration
Range
0.025-0.1%
Optimal
0.05%
Prescription use only. Lower concentrations (0.025%) are generally initiated to reduce retinoid dermatitis; 0.05-0.1% used for established tolerance or more severe photoaging.
Works Well With / Avoid
Works Well With
Use With Caution
Given its prescription status in most jurisdictions, combinations should be managed under medical supervision. Moisturizers are typically recommended to buffer irritation.
Commonly Found In
Global Regulation Summary
Overview of current status across major international markets.
Detailed Regional Status
| Region | Status | Max Conc. | Conditions | Source |
|---|---|---|---|---|
| πͺπΊ EU | Banned | - | - | Official β |
| πΊπΈ USA | Allowed | - | - | Official β |
| π―π΅ Japan | Allowed | - | - | Official β |
| π°π· Korea | Unknown | - | - | Official β |
| π¬π§ UK | Banned | - | Follows EU regulations (II/375) | Official β |
π Why Regulations Differ
Retinoic acid is banned in EU and UK cosmetics (Annex II/375) because it is classified as a drug substance with receptor-mediated biological activity, teratogenicity risk, and a well-established irritation profile that requires medical supervision. The EU draws a clear regulatory line between retinoic acid (prescription drug) and retinol/retinyl esters (cosmetic actives at restricted concentrations). Japan and the US permit its use under pharmaceutical (prescription) frameworks rather than cosmetic regulation, reflecting the same potency concerns through a different regulatory channel.
Recent Regulatory Changes
- β’ EU Regulation 1223/2009 Annex II entry 375 prohibits retinoic acid in all cosmetic products.
- β’ UK retained EU prohibition post-Brexit via the UK Cosmetics Regulation.
Regulation Analysis
Regional Agreement
Banned in EU, UK but allowed in USA, Japan.
Strictness Ranking
πΏ Natural Sources
Not found naturally. Derived from Vitamin A (retinol) through enzymatic oxidation in the body.
π How It's Made
Synthesized by chemical oxidation of retinaldehyde or retinol, typically using chromium trioxide or other oxidizing agents.
π Uses in Cosmetics
Tretinoin (all-trans retinoic acid) is banned in EU cosmetics (Annex II/375) and classified as a prescription drug in most countries. Used in pharmaceutical acne and anti-aging treatments at 0.01-0.1% concentration. Too potent and irritating for over-the-counter cosmetics, which use gentler retinol or retinaldehyde instead.
π¬ Other Applications
Pharmaceutical treatment for acne vulgaris, photoaged skin, and acute promyelocytic leukemia (oral form). Also used in research on cell differentiation and cancer.
π‘ Fun Facts
- β’ Tretinoin was FDA-approved for acne in 1971 as Retin-A, making it one of the oldest prescription retinoids still in use
- β’ EU bans retinoic acid in cosmetics but allows weaker retinol up to 0.3% in face products - highlighting the potency difference
- β’ Oral isotretinoin (Accutane) is a stereoisomer of retinoic acid and causes severe birth defects, requiring strict pregnancy prevention programs
Related Skin Concerns
Data Sources
- β’ Kligman AM et al. (1986). Journal of the American Academy of Dermatology, 15(4 Pt 2).
- β’ Griffiths CE et al. (1993). Archives of Dermatology, 129(4), 419-425.
- β’ EU Cosmetics Regulation (EC) No 1223/2009 Annex II entry 375.
- β’ FDA NDA 016987 (Retin-A) approval documents.
- β’ CIR Expert Panel retinoid safety assessments.
Last data verification: 2026-04-12
Related Ingredients
Learn More
Frequently Asked Questions
Why is RETINOIC ACID banned in the EU but allowed in the US?
The EU follows a precautionary principle, banning RETINOIC ACID under II/375 due to potential safety concerns. The US FDA has not found sufficient evidence to prohibit its use, allowing it under different safety assessment standards. This reflects differing regulatory philosophies between the two regions.
Why is RETINOIC ACID banned in the EU but allowed in Japan?
The EU prohibits RETINOIC ACID (II/375) based on their strict safety criteria. Japan's Ministry of Health, Labour and Welfare (MHLW) has evaluated the ingredient and permits its use, potentially with different safety data or usage conditions.
What is RETINOIC ACID used for in cosmetics?
RETINOIC ACID is primarily used for not reported in cosmetic products. The ingredient is commonly found in various cosmetic and personal care products.
Which countries regulate RETINOIC ACID?
RETINOIC ACID is banned in EU, UK. The ingredient is freely allowed in JP, US.
Are there alternatives to RETINOIC ACID?
Due to regulatory restrictions on RETINOIC ACID, cosmetic manufacturers often use alternative ingredients with similar functions. For not reported, alternatives may include other approved ingredients in the same category. Consult product labels for specific formulations, and look for products compliant with your region's regulations.
Disclaimer
The information on this website is for educational and informational purposes only and is not intended as medical advice. While we strive for accuracy based on official government databases, cosmetic regulations change frequently. Always consult with a qualified professional or refer to the latest official regulatory documents for compliance. We are not responsible for any actions taken based on the information provided here.